{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:12:48Z","timestamp":1778904768879,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clgc.2026.102562","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:34:26Z","timestamp":1776011666000},"page":"102562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Second-Line Radiation Therapy for Locally Recurrent Prostate Cancer After Focal Therapy: A Single Institution Matched-Pair Analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Agnes","family":"Ewongwo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4304-2265","authenticated-orcid":false,"given":"Nikitha V.","family":"Kalahasti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caressa","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kekoa","family":"Taparra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-1956","authenticated-orcid":false,"given":"Geoffrey","family":"Sonn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6393-0964","authenticated-orcid":false,"given":"Pejman","family":"Ghanouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary P.","family":"Bagshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark K.","family":"Buyyounouski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102562_bib0001","unstructured":"National Cancer Institute. Cancer stat facts: prostate cancer. Accessed May 27, 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"10.1016\/j.clgc.2026.102562_bib0002","unstructured":"SEER. Common cancer sites: cancer stat facts. Accessed May 27, 2025. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/common.html."},{"issue":"6","key":"10.1016\/j.clgc.2026.102562_bib0003","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamaoncol.2024.0734","article-title":"Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis","volume":"10","author":"Fazekas","year":"2024","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.clgc.2026.102562_bib0004","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate cancer screening with PSA and MRI followed by targeted biopsy only","volume":"387","author":"Hugosson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102562_bib0005","unstructured":"National Cancer Institute. SEER*Explorer application. Accessed May 27, 2025. Available at: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=66&data_type=1&graph_type=4&compareBy=race&chk_race_1=1&hdn_sex=2&age_range=1&advopt_precision=1&hdn_view=1&advopt_show_apc=on&advopt_display=2#resultsRegion1."},{"issue":"Suppl 2","key":"10.1016\/j.clgc.2026.102562_bib0006","first-page":"S3","article-title":"Management of clinically localized prostate cancer","volume":"6","author":"Lepor","year":"2004","journal-title":"Rev Urol"},{"key":"10.1016\/j.clgc.2026.102562_bib0007","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102562_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2021.696242","article-title":"Focal therapy for prostate cancer: complications and their treatment","volume":"8","author":"Rakauskas","year":"2021","journal-title":"Front Surg"},{"issue":"3","key":"10.1016\/j.clgc.2026.102562_bib0009","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/CCO.0000000000000515","article-title":"Contemporary treatments in prostate cancer focal therapy","volume":"31","author":"Ahdoot","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clgc.2026.102562_bib0010","unstructured":"Cleveland Clinic. Focal therapy for prostate cancer: procedure & side effects. Accessed May 27, 2025. Available at: https:\/\/my.clevelandclinic.org\/health\/treatments\/16265-prostate-cancer-focal-therapy."},{"issue":"4","key":"10.1016\/j.clgc.2026.102562_bib0011","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2018.06.006","article-title":"A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer","volume":"74","author":"Guillaumier","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102562_bib0012","article-title":"Survival outcomes and recurrence patterns following focal high-intensity focused ultrasound treatment for localized prostate cancer: insights on patient selection and lessons learned","author":"Nahar","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2026.102562_bib0013","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000000506","article-title":"Focal therapy for localized prostate cancer with either high intensity focused ultrasound or cryoablation: a single institution experience","author":"Tourinho-Barbosa","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102562_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvir.2025.05.024","article-title":"Magnetic resonance imaging-guided transurethral ultrasound ablation of localized prostate cancer (MRI-TULSA): a prospective trial","author":"Tricard","year":"2025","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.clgc.2026.102562_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2025.06.007","article-title":"Determining optimal patient selection for high-intensity focused ultrasound for prostate cancer","author":"Shee","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2026.102562_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1028858","article-title":"Salvage external beam radiotherapy after HIFU failure in localized prostate cancer: a single institution experience","volume":"12","author":"Di Lalla","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2026.102562_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110665","article-title":"Salvage radiotherapy with volumetric modulated arc therapy (VMAT) for recurrent prostate cancer after high-intensity focused ultrasound (HIFU): a large French retrospective series and literature review","volume":"203","author":"Baude","year":"2025","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102562_bib0018","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.ijrobp.2022.07.913","article-title":"Implementation and case study of a clinical research data warehouse in radiation oncology","volume":"114","author":"Qu","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2026.102562_bib0019","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE) Version 5.0. Protocol development: CTEP. Accessed May 27, 2025. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50."},{"key":"10.1016\/j.clgc.2026.102562_bib0020","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE) Version 6.0. Protocol development: CTEP. Accessed September 1, 2025. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.html."},{"issue":"4","key":"10.1016\/j.clgc.2026.102562_bib0021","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.clgc.2026.102562_bib0022","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1464-410X.2012.11715.x","article-title":"Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer","volume":"112","author":"Ganzer","year":"2013","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.clgc.2026.102562_bib0023","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.eururo.2013.04.039","article-title":"Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients","volume":"65","author":"Crouzet","year":"2014","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102562_bib0024","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.eururo.2010.06.003","article-title":"Salvage radiotherapy after high-intensity focussed ultrasound for recurrent localised prostate cancer","volume":"58","author":"Riviere","year":"2010","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102562_bib0025","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000345631","article-title":"Salvage external beam radiotherapy for recurrent prostate adenocarcinoma after high-intensity focused ultrasound as primary treatment","volume":"90","author":"Munoz","year":"2013","journal-title":"Urol Int"},{"issue":"5","key":"10.1016\/j.clgc.2026.102562_bib0026","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11547-020-01148-4","article-title":"Post-HIFU locally relapsed prostate cancer: high-dose salvage radiotherapy guided by molecular imaging","volume":"125","author":"Rigo","year":"2020","journal-title":"Radiol Med (Torino)"},{"issue":"5","key":"10.1016\/j.clgc.2026.102562_bib0027","first-page":"395","article-title":"11C choline PET guided salvage radiotherapy with volumetric modulation arc therapy and hypofractionation for recurrent prostate cancer after HIFU failure: preliminary results of tolerability and acute toxicity","volume":"13","author":"Alongi","year":"2014","journal-title":"Technol Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clgc.2026.102562_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41391-022-00535-4","article-title":"Prostate cancer intensity-modulated radiotherapy and long term genitourinary toxicity: an evolving therapeutic landscape","volume":"26","author":"Achard","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.clgc.2026.102562_bib0029","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41391-022-00520-x","article-title":"Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis","volume":"26","author":"David","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.clgc.2026.102562_bib0030","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.urology.2008.02.064","article-title":"Salvage radiotherapy after high-intensity focused ultrasound for localized prostate cancer: early clinical results","volume":"72","author":"Pasticier","year":"2008","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.clgc.2026.102562_bib0031","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ijrobp.2016.01.031","article-title":"Late side effects after image guided intensity modulated radiation therapy compared to 3D-conformal radiation therapy for prostate cancer: results from 2 prospective cohorts","volume":"95","author":"Wortel","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2026.102562_bib0032","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ctrv.2016.06.006","article-title":"Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer","volume":"48","author":"Zaorsky","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.clgc.2026.102562_bib0033","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eururo.2025.05.014","article-title":"Evolving risk of urinary adverse events across localized prostate cancer treatments: a propensity-weighted analysis of surveillance, epidemiology and end results-Medicare data","volume":"89","author":"Li","year":"2026","journal-title":"Eur Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:37:17Z","timestamp":1778902637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1558767326000625"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102562","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-Line Radiation Therapy for Locally Recurrent Prostate Cancer After Focal Therapy: A Single Institution Matched-Pair Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102562"}}